Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 94Leukemia 18Leukemia, Myeloid, Chronic-Phase 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Blast Crisis 8Myeloproliferative Disorders 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Philadelphia Chromosome 3Leukemia, Myeloid, Accelerated Phase 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Hematologic Neoplasms 2Piebaldism 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm, Residual 1Mastocytosis, Systemic 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1Gastrointestinal Stromal Tumors 1

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × nilotinib × Myeloid × Clear all
NCT01774630 2026-05-26

NiloPost-STIM

University Hospital, Bordeaux

Phase 2 Completed
31 enrolled
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Novartis

Phase 1 Completed
326 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Fred Hutchinson Cancer Center

Phase 2 Completed
28 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡